Cat. No. 3418
Biological ActivityEndogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptors. Inhibits glucagon secretion, delays gastric emptying and acts as a satiety agent. Displays glucose lowering effects in vivo.
(Modifications: Tyr-37 = C-terminal amide, Disulfide bridge between 2 - 7)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Hoogwerf et al (2008) Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc.Health Risk Manag. 4 355. PMID: 18561511.
Schmitz et al (2004) Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 S233. PMID: 15561917.
Castillo et al (1995) Amylin/islet polypeptide: biochemistry, physiology, patho-physiology. Diabete Metab. 21 3. PMID: 7781840.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Amylin from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Amylin, supplier, Endogenous, peptide, agonists, amylin, calcitonin, CGRP, adrenomedullin, receptors, Receptors, Amylin, CT, AMY, Calcitonin, Tocris Bioscience, Calcitonin and Related Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
March 18 - 22, 2017
Little Rock, ARK, USA